Skip to content

Total debt at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$32.79M-11.3%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$31.57M-33.1%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $15.48M.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s total debt?
Cogent Biosciences, Inc. (COGT) reported total debt of $15.48M in Q1 2026.
How has Cogent Biosciences, Inc.'s total debt changed year-over-year?
Cogent Biosciences, Inc.'s total debt decreased by 9.4% year-over-year, from $17.09M to $15.48M.
What is the long-term trend for Cogent Biosciences, Inc.'s total debt?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total debt has grown at a 25.0% compound annual growth rate (CAGR), from $5.21M to $15.9M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.